C12N 9/6462
U-plasminogen activator , i.e. urokinase
Official title: {u-Plasminogen activator (3.4.21.73), i.e. urokinase}
C12N9/6462 (U-plasminogen activator , i.e. urokinase) appears on 177 US grants and 113 published applications in this corpus.
Search patents in C12N- Granted patents
- 177
- Published applications
- 113
- Assignees
- 116
- Inventors
- 440
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 5 | 0 |
| 1978 | 2 | 0 |
| 1979 | 4 | 0 |
| 1980 | 3 | 0 |
| 1981 | 9 | 0 |
| 1982 | 6 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 10 | 0 |
| 1986 | 4 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 3 | 0 |
| 1991 | 8 | 0 |
| 1992 | 8 | 0 |
| 1993 | 4 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 3 | 0 |
| 1997 | 5 | 0 |
| 1998 | 6 | 0 |
| 1999 | 6 | 0 |
| 2000 | 3 | 0 |
| 2001 | 5 | 1 |
| 2002 | 3 | 5 |
| 2003 | 5 | 10 |
| 2004 | 5 | 10 |
| 2005 | 6 | 8 |
| 2006 | 8 | 5 |
| 2007 | 3 | 7 |
| 2008 | 3 | 3 |
| 2009 | 0 | 8 |
| 2010 | 5 | 3 |
| 2011 | 0 | 2 |
| 2012 | 3 | 5 |
| 2013 | 2 | 3 |
| 2014 | 3 | 5 |
| 2015 | 1 | 4 |
| 2016 | 2 | 1 |
| 2017 | 2 | 2 |
| 2018 | 3 | 4 |
| 2019 | 2 | 1 |
| 2020 | 0 | 4 |
| 2021 | 1 | 2 |
| 2022 | 2 | 4 |
| 2023 | 4 | 3 |
| 2024 | 1 | 3 |
| 2025 | 4 | 6 |
| 2026 | 2 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Protease substrate, and polypeptide including protease cleavage sequence14 Jul 2026US 12,680,093 B2Chugai Seiyaku Kabushiki Kaisha
- Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase31 Mar 2026US 12,590,301 B2Thrombolytic Science, Inc.
- Fusion protein suitable for dissolving fibrin clot, and pharmaceutical composition containing said fusion protein30 Dec 2025US 12,509,507 B2National Cancer Center
- suPAR and prediction and treatment of acute kidney injury9 Dec 2025US 12,492,250 B2Emory University
- Fusion proteins having a toxin and cancer marker, nanoparticles, and uses related thereto4 Nov 2025US 12,458,603 B2Emory University
- Method for the Production of Pharmaceutically Active Recombinant Human Low Molecular Weight Urokinase8 Oct 2026US 2026/0308654 A1Cerbios-Pharma SA
- Antibody binding to fibrin, fibrinolytic protein containing antibody, and pharmaceutical formulation containing protein27 Aug 2026US 2026/0250366 A1Rin Institute Inc.
- Targeting and lysing microthrombi associated with aberrant blood clotting7 May 2026US 2026/0125665 A1
- suPAR and Prediction and Treatment of Acute Kidney Injury12 Mar 2026US 2026/0070973 A1Emory University
- Stroma penetrating therapeutic t-cell engager for cancer immunotherapy9 Oct 2025US 2025/0312465 A1Emory University
Most cited
By later US patents
- Plasminogen activator derivatives616US 4,640,835 ANippon Chemiphar Co., Ltd. · 1987
- Purification and activity assurance of precipitated heterologous proteins229US 4,511,503 AGenentech, Inc. · 1985
- Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases229US 5,759,542 ANew England Deaconess Hospital Corporation · 1998
- Purification and activity assurance of precipitated heterologous proteins212US 4,511,502 AGenentech, Inc. · 1985
- Purification and activity assurance of precipitated heterologous proteins206US 4,512,922 AGenentech, Inc. · 1985